下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

FY2022 EPS Estimates for BioNTech SE Reduced by SVB Leerink (NASDAQ:BNTX)
SVB Leerink下调2022财年BioNtech SE每股收益预期(纳斯达克股票代码:BNTX)

Defense World ·  {{timeTz}}

BioNTech SE (NASDAQ:BNTX – Get Rating) – Investment analysts at SVB Leerink cut their FY2022 earnings per share (EPS) estimates for shares of BioNTech in a report issued on Tuesday, August 9th. SVB Leerink analyst D. Graybosch now expects that the company will post earnings of $33.38 per share for the year, down from their prior estimate of $39.49. SVB Leerink currently has a "Outperform" rating and a $224.00 target price on the stock. The consensus estimate for BioNTech's current full-year earnings is $35.28 per share. SVB Leerink also issued estimates for BioNTech's Q4 2022 earnings at $9.93 EPS, Q1 2023 earnings at $6.36 EPS, Q3 2023 earnings at $4.09 EPS, FY2023 earnings at $22.16 EPS and Q1 2024 earnings at ($0.01) EPS.

纳斯达克股票代码:BNTX-GET Rating)-SVB Leerink的投资分析师在8月9日(星期二)发布的一份报告中下调了对BioNTech股票的2022财年每股收益预期。SVB Leerink分析师D.GrayBosch现在预计,该公司今年的每股收益将为33.38美元,低于此前预测的39.49美元。SVB Leerink目前对该股的评级为“跑赢大盘”,目标价为224.00美元。对BioNTech目前全年收益的普遍预期为每股35.28美元。SVB Leerink还发布了对BioNTech 2022年第四季度每股收益9.93美元、2023年第一季度每股收益6.36美元、2023年第三季度每股收益4.09美元、2023财年每股收益22.16美元和2024年第一季度每股收益(0.01美元)的预期。

Get
到达
BioNTech
BioNTech
alerts:
警报:

Several other research analysts have also recently issued reports on BNTX. Jefferies Financial Group set a $230.00 price target on BioNTech in a research note on Monday, May 9th. Morgan Stanley cut their price objective on BioNTech from $195.00 to $194.00 and set an "equal weight" rating for the company in a report on Friday, July 15th. Canaccord Genuity Group restated a "buy" rating and issued a $192.00 price objective on shares of BioNTech in a report on Wednesday, July 6th. Canaccord Genuity Group upped their price objective on BioNTech from $192.00 to $200.00 and gave the company a "buy" rating in a report on Tuesday. Finally, HC Wainwright cut their price objective on BioNTech from $283.00 to $272.00 and set a "buy" rating for the company in a report on Wednesday. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, BioNTech has a consensus rating of "Moderate Buy" and an average target price of $235.62.

其他几位研究分析师最近也发布了关于BNTX的报告。杰富瑞金融集团在5月9日星期一的一份研究报告中为BioNTech设定了230.00美元的目标价。摩根士丹利在7月15日星期五的一份报告中将他们对BioNtech的目标价从195.00美元下调至194.00美元,并对该公司设定了“同等权重”的评级。佳能基因集团在7月6日星期三的一份报告中重申了“买入”评级,并对BioNtech的股票发布了192.00美元的目标价。Cancord Genuity Group在周二的一份报告中将BioNtech的目标价从192.00美元上调至200.00美元,并给予该公司“买入”评级。最后,HC Wainwright将BioNtech的目标价从283.00美元下调至272.00美元,并在周三的一份报告中为该公司设定了买入评级。6名股票研究分析师对该股的评级为持有,6名分析师对该公司的评级为买入。根据MarketBeat的数据,BioNTech的共识评级为“中等买入”,平均目标价为235.62美元。

BioNTech Price Performance

BioNTech价格表现

Shares of BNTX opened at $158.59 on Thursday. BioNTech has a 12 month low of $117.08 and a 12 month high of $391.57. The company has a market cap of $38.54 billion, a P/E ratio of 3.06 and a beta of -0.08. The stock has a fifty day moving average price of $154.63 and a 200 day moving average price of $157.43. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.15 and a quick ratio of 4.93.
周四,BNTX的股价开盘报158.59美元。BioNtech的12个月低点为117.08美元,12个月高位为391.57美元。该公司市值为385.4亿美元,市盈率为3.06倍,贝塔系数为-0.08。该股的50日移动均价为154.63美元,200日移动均价为157.43美元。该公司的债务权益比为0.01,流动比率为5.15,速动比率为4.93。

BioNTech (NASDAQ:BNTX – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The company reported $6.45 EPS for the quarter, missing analysts' consensus estimates of $7.08 by ($0.63). The company had revenue of $3.20 billion for the quarter, compared to the consensus estimate of $4.11 billion. BioNTech had a return on equity of 88.76% and a net margin of 55.43%. BioNTech's quarterly revenue was down 39.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $12.98 earnings per share.

生物科技(纳斯达克代码:BNTX-GET Rating)最近一次发布季度收益数据是在8月8日星期一。该公司公布本季度每股收益为6.45美元,低于分析师普遍预期的7.08美元(0.63美元)。该公司本季度营收为32亿美元,而市场普遍预期为41.1亿美元。BioNTech的股本回报率为88.76%,净利润率为55.43%。与去年同期相比,BioNTech的季度收入下降了39.8%。去年同期,该公司每股收益为12.98美元。

Institutional Trading of BioNTech

生物技术的制度性交易

Hedge funds have recently made changes to their positions in the company. KRS Capital Management LLC acquired a new position in BioNTech in the fourth quarter valued at approximately $25,000. Koshinski Asset Management Inc. bought a new stake in shares of BioNTech during the first quarter valued at approximately $26,000. Covestor Ltd bought a new stake in shares of BioNTech during the fourth quarter valued at approximately $47,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in shares of BioNTech by 66.7% during the first quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 250 shares of the company's stock valued at $43,000 after acquiring an additional 100 shares in the last quarter. Finally, DeDora Capital Inc. bought a new stake in shares of BioNTech during the first quarter valued at approximately $51,000. 14.42% of the stock is owned by institutional investors and hedge funds.

对冲基金最近对他们在该公司的头寸进行了调整。KRS资本管理公司在第四季度收购了BioNTech的一个新头寸,价值约为25,000美元。Koshinski Asset Management Inc.在第一季度购买了BioNTech的新股,价值约2.6万美元。Covestor Ltd在第四季度购买了BioNTech的新股份,价值约47,000美元。洛林·沃尔科特和柯立芝信托顾问公司LLP MA在第一季度增持了66.7%的BioNTech股票。洛林·沃尔科特和柯立芝信托顾问公司现在拥有250股该公司的股票,价值43,000美元,在上个季度又购买了100股。最后,DeDora Capital Inc.在第一季度购买了BioNTech的新股,价值约51,000美元。14.42%的股票由机构投资者和对冲基金持有。

BioNTech Company Profile

BioNTech公司简介

(Get Rating)

(获取评级)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

BioNTech SE是一家生物技术公司,开发和销售治疗癌症和其他传染病的免疫疗法。该公司正在开发FixVac候选产品,包括治疗晚期黑色素瘤的第二阶段临床试验的BNT111、治疗前列腺癌的第一阶段/第二阶段临床试验的BNT112、治疗HPV阳性头颈癌的第二阶段临床试验的BNT113、治疗三阴性乳腺癌的第一阶段临床试验的BNT114、治疗卵巢癌的第一阶段临床试验的BNT115以及治疗非小细胞肺癌的临床前阶段产品BNT116。

Featured Stories

专题报道

  • Get a free copy of the StockNews.com research report on BioNTech (BNTX)
  • Look at Honeywell for a Steady and Diversified Stock
  • Why Invest in High-Yield Dividend Stocks?
  • Find and Profitably Trade Stocks at 52-Week Lows
  • Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
  • Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
  • 免费获取StockNews.com关于BioNTech的研究报告(BNTX)
  • 霍尼韦尔看好稳定和多元化的股票
  • 为什么要投资高收益股利股票?
  • 找到并获利于52周低点的股票交易
  • 迪士尼(NYSE:DIS)的股票刚刚给了投资者一个巨大的信号
  • 清洁能源法案通过后,太阳能股大放异彩

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.

获得《BioNTech Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioNTech和相关公司的最新新闻和分析师评级的每日简要摘要。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。